

CITATION REPORT

List of articles citing

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC

DOI: 10.1111/jdv.13354

Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-94.

Source: <https://exaly.com/paper-pdf/61361893/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
324	Management of psoriasis patients with hepatitis B or hepatitis C virus infection. 2016 , 22, 6444-55		29
323	Assessment and monitoring of biologic drug adverse events in patients with psoriasis. <i>Psoriasis: Targets and Therapy</i> , 2016 , 6, 41-54	2.4	3
322	Medical Informatics applied in psoriasis diagnosis and management. 2016 , 22, 62-67		
321	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. 2016 , 17, 217		47
320	Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30 Suppl 2, 1-18	4.6	78
319	Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. 2016 , 175, 873-881		26
318	Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. 2016 , 175, 250-62		32
317	Serbian Association of Dermatovenereologists Guidelines for the Diagnosis and Treatment of Psoriasis. 2016 , 8, 61-78		0
316	"Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis. 2016 , 14, 1090-1101		2
315	Psoriasis and Adherence to Therapy: Individual, Treatment-Related and General Factors. 2016 , 101-119		1
314	[Current guidelines in dermatology : A selection of clinically relevant recommendations]. 2016 , 67, 391-6		0
313	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. 2016 , 232, 385-406		31
312	Pathophysiological basis of systemic treatments in psoriasis. 2016 , 14, 557-72		5
311	Psoralen-ultraviolet A endures as one of the most powerful treatments in dermatology: reinforcement of this 'triple-product therapy' by the 2016 British guidelines. 2016 , 174, 11-4		17
310	Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. 2016 , 30, 371-8		9
309	Psoriasis. 2016 , 2, 16082		327
308	Drug survival rates and reasons for drug discontinuation in psoriasis. 2016 , 14, 1089-1099		43

307	Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. 2016 , 30, 469-480		20
306	Considerations for Systemic Treatment of Psoriasis in Obese Patients. 2016 , 17, 609-615		29
305	Multiple sclerosis: Dimethyl fumarate is coming of age. 2016 , 12, 436-7		4
304	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. 2016 , 7, 11724		36
303	Pathophysiologische Grundlagen der Systemtherapien bei Psoriasis. 2016 , 14, 557-73		10
302	Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. 2017 , 177, 497-504		14
301	Apremilast: A Review in Psoriasis and Psoriatic Arthritis. 2017 , 77, 459-472		93
300	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1183-1187	4.6	14
299	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 774-790	4.6	94
298	Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. 2017 , 18, 147-158		22
297	Certolizumab pegol for the treatment of psoriasis. 2017 , 17, 387-394		15
296	"Evergreen" Psoriasis - Neues zu Genetik, Therapie, und Berhaut. 2017 , 15, 111-112		1
295	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. 2017 , 121, 158-168		17
294	Real world prescription trends of methotrexate for psoriasis in Argentina: results of a national survey. 2017 , 28, 631-634		1
293	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. 2017 , 177, e325-e326		16
292	Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. 2017 , 77, 88-97.e5		63
291	Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis. 2017 , 42, 675-676		15
290	"Inflammatory skin march" in atopic dermatitis and psoriasis. 2017 , 66, 833-842		51

289	Update in the management of pediatric psoriasis. 2017 , 29, 434-442		8
288	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. 2017 , 177, 1024-1032		39
287	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. 2017 , 177, 1014-1023		116
286	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 2046-2054 ^{4,6}		20
285	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. 2017 , 177, 1410-1421		19
284	Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1475-1482 ^{4,6}		18
283	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1483-1490	4.6	27
282	Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). 2017 , 176, 1599-1606		11
281	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. 2017 , 177, 637-644		5
280	Optimizing acitretin use in patients with plaque psoriasis. <i>Dermatologic Therapy</i> , 2017 , 30, e12453	2.2	11
279	Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series. 2017 , 176, 803-805		1
278	Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1964-1977	4.6	5
277	First-line systemic treatment of psoriasis: staying conventional or going biologic?. 2017 , 177, 897-898		1
276	Treatment of severe psoriasis in children: recommendations of an Italian expert group. 2017 , 176, 1339-1354		39
275	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. 2017 , 153, 1147-1157		50
274	European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1951-1963	4.6	86
273	Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. <i>Dermatologic Therapy</i> , 2017 , 30, e12522	2.2	6
272	Certolizumab pegol, ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave?. 2017 , 32, 644-649		

271	[Psoriatic patients: Analysis of patients dissatisfied with their management]. 2017 , 144, 497-507		0
270	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritis. 2017 , 53, 371-393		30
269	Apremilast in psoriasis: a profile of its use. 2017 , 33, 361-367		1
268	Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIb PSO-INSIGHTFUL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1876-1883	4.6	24
267	Drug survival of methotrexate in psoriasis. 2017 , 177, 345-346		2
266	Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease. 2017 , 996, 287-294		19
265	[Topical therapy of the scalp]. 2017 , 68, 478-482		2
264	Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). 2017 , 28, 394-400		8
263	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm - and placebo-controlled trial (BRIDGE). 2017 , 176, 615-623		73
262	Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. 2017 , 137, 313-321		64
261	A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. 2017 , 176, 624-633		32
260	JEADV on the rise. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1945-1946		0
259	Maladies inflammatoires : les défis de la chronicité en 2016. 2017 , 144 Suppl 2, IIS8-IIS12		
258	Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar [®]) in Patients with Plaque Psoriasis under Daily Practice Conditions. 2017 , 233, 425-434		23
257	Old and New Biological Therapies for Psoriasis. 2017 , 18,		125
256	Treatment Approaches to Moderate to Severe Psoriasis. 2017 , 18,		54
255	Drug-induced psoriasis: clinical perspectives. <i>Psoriasis: Targets and Therapy</i> , 2017 , 7, 87-94	2.4	38
254	Brodalumab: A Review in Moderate to Severe Plaque Psoriasis. 2018 , 78, 495-504		15

253	Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. 2018 , 35, 135-144		32
252	A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. 2018 , 27, 611-624		59
251	Secukinumab in multi-failure psoriatic patients: the last hope?. 2018 , 29, 583-585		10
250	Update on Oral Therapy for Psoriasis. 2018 , 7, 52-58		1
249	Patient preference study for different characteristics of systemic psoriasis treatments (Protimis). <i>Dermatologic Therapy</i> , 2018 , 31, e12592	2.2	3
248	The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS). <i>Dermatology and Therapy</i> , 2018 , 8, 45-56	4	14
247	Autoimmunity and autoimmune co-morbidities in psoriasis. 2018 , 154, 21-27		28
246	Fumaric Acid Esters in Dermatology. 2018 , 199-208		0
245	Utilization of Biologic and Systemic Agents in the Elderly. 2018 , 281-294		
244	Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. 2018 , 84, 1776-1788		21
243	Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data. 2018 , 310, 475-483		17
242	Efficacy and safety of direct-acting antiviral agents when combined with secukinumab. 2018 , 25, 53-56		1
241	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. 2018 , 19, 209-222		24
240	Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 245-253	4.6	20
239	Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis. 2018 , 78, 123-130		38
238	[Drug therapy of acne inversa]. 2018 , 69, 58-63		5
237	Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. 2018 , 179, 16-29		26
236	Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study. 2018 , 178, 682-688		16

235	Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. 2018 , 178, 400-405		4
234	Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. 2018 , 55, 295-311		40
233	Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. 2018 , 19, 907-918		21
232	Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain. 2018 , 10, 747-759		3
231	Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?. 2018 , 153, 872-876		4
230	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32 Suppl 3, 3-14	4.6	41
229	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. 2018 , 179, 1385-1391		15
228	Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: Real-world data from a nationwide cohort study in Taiwan. 2018 , 79, 652-658		9
227	Differential efficacy of biologic treatments targeting the TNF- α /IL-23/IL-17 axis in psoriasis and psoriatic arthritis. 2018 , 111, 182-188		36
226	Psoriasis. 2018 , 677-702		0
225	Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2178-2184	4.6	3
224	The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept. 2018 , 22, 471-474		6
223	Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. 2018 , 18, 821-827		16
222	An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. 2018 , 18, 897-903		26
221	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. 2018 , 9, 579		102
220	Psoriasis vulgaris Bathophysiology of the disease and its classical treatment versus new drug delivery systems. 2018 , 379-406		6
219	Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. <i>Psoriasis: Targets and Therapy</i> , 2018 , 8, 21-29	2.4	10
218	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2058-2073	4.6	33

217	How to weight patient-relevant treatment goals for assessing treatment benefit in psoriasis: preference elicitation methods vs. rating scales. 2018 , 310, 567-577		3
216	Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1710-1727	4.6	12
215	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1920-1929	4.6	6
214	Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2191-2199	4.6	11
213	Measuring the importance of health domains in psoriasis - discrete choice experiment versus rating scales. 2018 , 12, 363-373		2
212	A new cover - reflecting a move forward for our Journal. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1399-1400	4.6	
211	Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals. 2018 , 109, 631-642		0
210	Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. 2018 , 41, 659-669		2
209	Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals. 2018 , 109, 631-642		0
208	Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. <i>Dermatologic Therapy</i> , 2019 , 32, e13051	2.2	5
207	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). 2019 , 311, 753-760		5
206	Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. 2019 , 10, 1808		31
205	Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. 2019 , 7, 1350-1351		7
204	A real-life experience of psoriatic patients with history of cancer treated with biological drugs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e453-e455	4.6	7
203	Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. 2019 , 39, 1510-1519		36
202	Cytopenia induced by low-dose methotrexate: An analysis of 433 cases from the French pharmacovigilance database. 2019 , 67, 97-101		1
201	A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis. 2019 , 110, 546-553		1
200	Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. 2019 , 13, 1993-2000		6

199	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2313-2318	4.6	
198	Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria. 2019 , 131, 485-492		4
197	Long-term use of fumaric acid esters for the treatment of psoriasis in daily practice. 2021 , 32, 610-616		0
196	Hyaluronic Acid-Based Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis. 2019 , 11, 43588-43598		86
195	Umstellung der Psoriasis-Therapie von einem Fumarsäureestergemisch auf ein Dimethylfumarat-Monopräparat: Ergebnisse einer prospektiven Studie. 2019 , 17, 906-912		1
194	Remicade (infliximab): 20 years of contributions to science and medicine. 2019 , 13, 139-178		36
193	Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 893-905	4.6	4
192	Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus. 2019 , 81, 228-240		43
191	Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study. 2019 , 8,		14
190	Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis. 2019 , 20,		37
189	Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. 2019 , 30, 311-319		12
188	Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. 2019 , 73, 442-450		11
187	Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. 2019 , 47, 2342-2350		10
186	Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. 2019 , 2019, 228424031882228		1
185	Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice. <i>Dermatologic Therapy</i> , 2019 , 32, e12875	2.2	7
184	Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. 2019 , 20, 295-306		13
183	French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 464-483	4.6	59
182	Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1249-1260	4.6	16

181	Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e215-e217	4.6
180	[Ciclosporin]. 2019 , 146, 466-469	1
179	[Psoriasis and HIV infection, what do French dermatologists do?]. 2019 , 146, 265-272	0
178	[Acitretin]. 2019 , 146, 454-458	1
177	The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. 2019 , 14, e0225112	12
176	Fire needle acupuncture or moxibustion for chronic plaque psoriasis: study protocol for a randomized controlled trial. 2019 , 20, 674	6
175	[Methotrexate]. 2019 , 146, 459-465	0
174	Daily practices regarding safety monitoring of low-dose methotrexate and comparison to guidelines: A population-based cohort study. 2021 , 76, 425-433	0
173	Psoriasis. 2019 , 368-375	
172	Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. 2019 , 180, 409-410	13
171	Renal clearance and intracellular half-life essentially determine methotrexate toxicity: A case series. 2019 , 5, 98-100	6
170	Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. 2019 , 80, 43-53	149
169	Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. 2019 , 80, 27-40	177
168	IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. 2019 , 16, 185-196	170
167	Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. 2019 , 23, 204-221	21
166	Psoriasis and cardiovascular disease: the elusive link. 2019 , 38, 33-54	13
165	Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. 2019 , 180, 31-42	14
164	Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. 2019 , 139, 638-647	38

163	Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study. 2019 , 17, 906-912		7
162	Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 700-708	4.6	37
161	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. 2019 , 30, 461-465		12
160	Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 553-559	4.6	33
159	Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PATient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 340-354	4.6	13
158	A statistical method to convert published response rates into marginal distributions with an example application in psoriasis. 2019 , 18, 4-21		1
157	The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. 2020 , 31, 213-221		6
156	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. 2020 , 31, 344-351		5
155	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. 2020 , 82, 117-122		46
154	Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study. 2020 , 82, 37-44		6
153	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. 2020 , 182, 869-879		15
152	DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. 2020 , 182, 1167-1175		13
151	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOSEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 293-300	4.6	20
150	Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. 2020 , 50, 36-41		2
149	Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. 2020 , 31, 769-775		15
148	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). 2020 , 183, 265-275		14
147	Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 310-318	4.6	13
146	Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 119-126	4.6	4

145	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. 2020 , 16, 119-128		4
144	Japanese guidance for use of biologics for psoriasis (the 2019 version). 2020 , 47, 201-222		26
143	Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IB 2020 , 79, 106045		3
142	Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. 2020 , 4, rkaa033		1
141	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. 2020 , 111, 752-760		3
140	Practical compendium for psoriasis management. <i>Dermatologic Therapy</i> , 2020 , 33, e13243	2.2	2
139	Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. 2020 , 1-7		3
138	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. 2020 , 37, 3732-3745		3
137	The role of xenobiotics in triggering psoriasis. 2020 , 94, 3959-3982		2
136	Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents. 2020 , 1-14		2
135	Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. 2020 , 8, 1031-1044		4
134	Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). 2020 , 37, 428-434		3
133	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. 2020 , 111, 752-760		
132	Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. 2020 , 9, 165-178		22
131	Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. 2020 , 45, 824-830		8
130	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2839-2845	4.6	4
129	Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. <i>Dermatology and Therapy</i> , 2020 , 10, 589-613	4	14
128	Axial Spondyloarthritis in the Era of Precision Medicine. 2020 , 46, 367-378		0

127	Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. 2020 , 34, 235-244		8
126	Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2339-2345	4.6	6
125	Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. 2020 , 11, 2040622320904295		1
124	Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. 2020 , 80, 1235-1245		11
123	Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis. 2020 , 31, 460-469		0
122	Effects of moving cupping therapy for plaque psoriasis: study protocol for a randomized multicenter clinical trial. 2020 , 21, 229		5
121	Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1257-1262	4.6	6
120	Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care. 2021 , 32, 898-906		
119	Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. 2020 , 40, 969-981		3
118	The unforeseen during biotechnological therapy for moderate-to-severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1211-1214	2.2	2
117	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 912-918	4.6	0
116	Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. 2021 , 84, 1310-1320		20
115	Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis. 2021 , 157, 198-201		8
114	Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. 2021 , 185, 62-73		1
113	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. 2021 , 21, 75-80		2
112	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 417-421	4.6	3
111	Profile of Psoriasis Vulgaris Patients Treated with Methotrexate at Dr. Soetomo Hospital, Surabaya, 2017-2018. 2021 , 9, 70		
110	Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice. 2021 , 274-283		

109	Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)- β antagonists versus TNF- α antagonists alone in psoriatic patients. 2021 , 48, 835-843	3
108	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. 2021 , 1-9	4
107	Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. 2021 , 1-5	4
106	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 281-317 ^{4,6}	19
105	Moxibustion therapy for treating psoriasis vulgaris: A protocol for systematic review and meta-analysis. 2021 , 100, e25250	1
104	Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis. 2021 , 17, 611-611	
103	Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. 2021 , 11,	10
102	Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. 2021 , 1-36	1
101	Fire needle therapy for blood stasis syndrome of plaque psoriasis: A protocol for systematic review and meta-analysis. 2021 , 100, e25312	
100	Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. <i>Dermatologic Therapy</i> , 2021 , 34, e14974	2.2
99	Subclinical Cardiac Organ Damage in Patients with Moderate to Severe Psoriasis. 2021 , 10,	1
98	Immunotherapy in psoriasis. 2021 , 13, 605-619	2
97	Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis. 2021 , 10,	0
96	Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. 2021 , 60, 1140-1147	1
95	Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. 2021 , 138, 111456	5
94	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. 2021 , 84, 1636-1643	11
93	Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?. 2021 , 1-9	
92	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. 2021 , 19, 1092-1115	3

91	Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis. 2021 , 17, 611-621		
90	Effectiveness of Mind-Body Intervention for Inflammatory Conditions: Results from a 26-Week Randomized, Non-Blinded, Parallel-Group Trial. 2021 , 10,		0
89	Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study. 2021 , 1-4		1
88	Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidit�. 2021 , 19, 1092-1117		5
87	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). 2021 , 1-15		1
86	Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1'326'312 patients in France. 2021 ,		3
85	Direct comparison of risankizumab and fumaric acid esters in systemic therapy-na�ve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. 2021 ,		2
84	Spontaneous hydrolysis and spurious metabolic properties of �ketoglutarate esters. 2021 , 12, 4905		6
83	Treatment Patterns and Resource Utilization of Pregnant Women with Inflammatory Rheumatic Diseases or Psoriasis in Germany: A Claims Database Analysis. 2021 , 8, 1565-1584		0
82	Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease. 2021 , 8, 696597		2
81	Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis. 2021 , 157, 1056-1065		11
80	Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. 2021 , 48, 1854-1862		2
79	A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. 2021 ,		8
78	Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. 2021 , 335, 98-109		0
77	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021 , 11, 235-252	4	11
76	Topical medications for chronic plaque psoriasis: A 3-year longitudinal study in France. <i>Dermatologic Therapy</i> , 2021 , 34, e14781	2.2	
75	A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis. 2019 , 110, 546-553		10
74	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). 2021 , 32, 883-893		3

73	TNF-inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. 2020 , 16, 591-598		7
72	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2461-2498	4.6	36
71	Asymptomatic reactivation of hepatitis B virus after prolonged treatment with etanercept. 2019 , 28,		0
70	Hard-to-treat psoriasis in a child developing neutralizing anti-drug antibodies against adalimumab during Streptococcus pyogenes throat infection: a case report. 2020 , 29,		0
69	Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. 2020 , 18, 592-609		3
68	The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio. 2019 , 31, 601-610		4
67	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. 2021 , 53, 1727-1736		1
66	Can the Enhanced Liver Fibrosis score be used to Diagnose Children with Liver Fibrosis?. 2021 , 74,		0
65	Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy.. 2022 , 113, 261-277		2
64	Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis. 2021 , 156,		
63	A Review of Possible Triggering or Therapeutic Effects of Antimicrobial Vaccines on Psoriasis.		
62	Psoriasis. 2018 , 1-26		
61	Literatur. 2018 , 607-621		
60	Thérapeutiques ciblées dans les maladies inflammatoires cutanées. 2018 , 202, 1939-1945		
59	Dermatology Part 2: Ichthyoses and Psoriasis. 2020 , 261, 153-175		
58	Effects of Moving Cupping Therapy for Plaque Psoriasis: A Protocol for a Randomised Multicentre Clinical Trial.		
57	Evaluation of IHC Ki-67 with Clinical Correlation in Psoriasis. 2020 , 12, 33-40		0
56	The Actual Challenges of Biologics Treatment in Patients with Psoriasis. <i>Vestnik Dermatologii i Venerologii</i> , 2020 , 96, 51-57	0.4	1

55	Results of the long-term observational noninterventional prospective study BODYGUARD in psoriasis patients. <i>Vestnik Dermatologii I Venerologii</i> , 2019 , 95, 87-93	0.4	0
54	Immunohistochemical analysis of FOXP3+ T-regulatory cells and its role in evaluating the effectiveness of psoriasis therapy. 2020 , 19, 24		
53	Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis. 2020 , 11, 373-401		
52	Psoriasis. 2020 , 1-24		
51	Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#. 2020 , 3, 14-26		0
50	Ankylosing Spondylitis. 2022 , 371-403		
49	Summary of Published Treatment Guidelines. 2021 , 399-414		
48	Systemic treatment of psoriasis: from methotrexate to biologics. <i>Vestnik Dermatologii I Venerologii</i> , 2020 , 96, 7-26	0.4	0
47	A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors.. 2021 , 13, 11795735211037798		1
46	Analytical Method Development and Validation of Etanercept by UV and RP-UFLC Methods. 2021 , 12, 493-505		0
45	Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF- α) Blocking Biologic Drugs: One-Year Dynamic Observation. 2021 , 75, 357-363		
44	The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine Syndromes.. 2021 , 12, 759741		0
43	Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.. 2022 , 15,		2
42	Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages.. 2021 , 9, 816757		1
41	A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.. <i>Dermatologic Therapy</i> , 2022 , e15339	2.2	1
40	Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.. <i>Dermatology and Therapy</i> , 2022 , 12, 511	4	1
39	Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic.. <i>Dermatology and Therapy</i> , 2022 , 1	4	2
38	Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates. 2022 , 3, 17-34		

37	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy.. 2022,		0
36	The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway.. 2022, 9, 760852		0
35	Development of a Patient Reported Experience Measure (PREM) for Chronic Inflammatory Skin Diseases.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022,	4.6	1
34	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.. <i>Psoriasis: Targets and Therapy</i> , 2021, 11, 151-168	2.4	3
33	Laboratory Monitoring: HIV, TB and Hepatitis. 2022, 9-24		
32	Aktualisierte S3-Leitlinie Diagnostik und Therapie des Morbus Crohn der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) August 2021 AWMF-Registernummer: 021-004. 2022, 60, 332-418		5
31	Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr).. 2022, 24, 281		0
30	Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas.. <i>Dermatology and Therapy</i> , 2022, 12, 1121	4	0
29	Data_Sheet_1.docx. 2019,		
28	Cost per responder of adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.. 2022,		1
27	Psoriasis. 2022, 673-696		
26	Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.. 2022,		
25	Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. 2022, 10, 646		2
24	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.. <i>Dermatology and Therapy</i> , 2022, 1	4	
23	Treatment algorithms for special cases. <i>Turkderm</i> , 80-85	2	
22	Ustekinumab. <i>Turkderm</i> , 48-51	2	
21	Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients. <i>Vestnik Dermatologii i Venerologii</i> , 2017, 93, 38-45	0.4	1
20	The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. <i>International Journal of Women's Dermatology</i> , 2022, 8, e010	2	0

19	Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: A cross-sectional study in Italy. <i>Dermatologic Therapy</i> ,	2.2	0
18	The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. <i>Dermatologica Sinica</i> , 2022 , 40, 94	1.1	
17	Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience. <i>Psoriasis: Targets and Therapy</i> , Volume 12, 177-185	2.4	
16	Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. <i>Journal of Controlled Release</i> , 2022 , 349, 354-366	11.7	1
15	Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level.		1
14	Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab. 2022 , 36, 039463202211111		0
13	Incidence, Risk Factors, and Consequences of Human Alphaherpesvirus Infections in Patients With Psoriasis Who Initiate Methotrexate or Biologic Agents.		0
12	Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.		0
11	Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. 2022 , 18, 1033-1047		3
10	Tailored biological treatment for patients with moderate to severe psoriasis.		0
9	Sociology: The Departure of Btray Colleagues in a Vaguely Cognate Discipline□ 2022 , 691-763		0
8	Busting the myth of methotrexate chronic hepatotoxicity.		0
7	Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).		0
6	Liver Disease Among Patients with Psoriasis: The Malaysian Psoriasis Registry.		0
5	Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus.		0
4	Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China. Volume 16, 443-451		0
3	Proyecto CUDERMA: Consenso Delphi de los indicadores de calidad para la certificaci3n de las unidades de dermatolog3a de atenci3n en psoriasis. 2023 ,		0
2	Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles. 2023 , 24, 4556		0

- 1 Association between methotrexate-induced Stevens-Johnson syndrome/toxic epidermal necrolysis and furosemide: a real-world disproportionality analysis. 1-8

o